Ischemia-modified albumin use as a prognostic factor in coronary bypass surgery

Basit Öğe Kaydı
dc.contributor.authorKanko, Muhip
dc.contributor.authorYavuz, Sadan
dc.contributor.authorDuman, Can
dc.contributor.authorHosten, Tulay
dc.contributor.authorOner, Emin
dc.contributor.authorBerki, Turan
dc.date.accessioned2025-01-27T20:22:23Z
dc.date.available2025-01-27T20:22:23Z
dc.date.issued2012
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: Various types of markers have been used so far in order to reveal myocardial perfusion defect. However, these markers usually appear in the necrosis phase or in the late stage. Having been the focus of various investigations recently, ischemia-modified albumin (IMA) is helpful in establishing diagnosis in the early stages of ischemia, before necrosis develops. Methods and Results: 30 patients that underwent only coronary bypass surgery due to ischemic heart disease within a specific period of time have been included in the study. IMA levels were studied in the preoperative, intraoperative, and postoperative periods. The albumin cobalt binding assay was used for IMA determination. Hemodynamic parameters (atrial fibrillation, the need for inotropic support, ventricular arrhythmia) of the patients in the postoperative stage were evaluated. Intraoperative measurement values (mean +/- SD) of IMA (0.67677 +/- 0.09985) were statistically significantly higher than those in the preoperative (0.81516 +/- 0.08894) and postoperative (0.70477 +/- 0.07523) measurements. Considering atrial fibrillation and need for inotropics, a parallelism was detected with the levels of IMA. Conclusions: IMA is an early-rising marker of cardiac ischemia and enables providing a direction for the treatment at early phases.
dc.identifier.doi10.1186/1749-8090-7-3
dc.identifier.issn1749-8090
dc.identifier.pmid22221979
dc.identifier.scopus2-s2.0-84855373068
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/1749-8090-7-3
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21861
dc.identifier.volume7
dc.identifier.wosWOS:000300888400001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBiomed Central Ltd
dc.relation.ispartofJournal of Cardiothoracic Surgery
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectCoronary artery bypass surgery
dc.subjectischemia-modified albumine
dc.subjectmyocardial ischaemia
dc.titleIschemia-modified albumin use as a prognostic factor in coronary bypass surgery
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu